What is GLORY-1?
GLORY-1 is an innovative investigational therapy in the field of metabolic health, designed as a dual receptor agonist targeting both…
Tag: GLP-1
China’s Breakthrough Obesity Drug Mazdutide Achieves Record Weight Loss in Global Study
A landmark Phase 3 clinical study of mazdutide, the world’s first dual glucagon (GCG)/glucagon-like peptide-1 (GLP-1) receptor agonist, has been…
7 Warning Signs of Obesity: Don’t Ignore These Red Flags
Obesity isn’t just about weight—it’s a complex medical condition linked to serious health risks like diabetes, heart disease, and cancer. But…
Top Obesity Drug Stocks to Watch: The Companies Leading the Weight-Loss Revolution
The global obesity drug market is experiencing significant growth, with projections exceeding $150 billion annually in the coming decade. This…
Weight-Loss Jabs Could Slash Cancer Risk by 50%: A “Transformational” Breakthrough
Key Findings at a Glance The Study: How Weight-Loss Drugs Stack Up Against Surgery A landmark Israeli study (presented at the European Congress…
Frequent Asked Questions about Obesity
Obesity is one of the most misunderstood health crises of our time. Below, we tackle the most pressing questions—backed by…
10 Powerful Ways Technology Supports Weight Loss
Artificial Intelligence (AI) is transforming healthcare—and it’s now playing a critical role in tackling one of the world’s most pressing…